Traumeel Injections in Soft
Tissue Complaints
Traumeel is a substance
that contains homeopathic components, including arnica. No major studies have been performed to examine its effects. It may
promote healing and reduce inflammation and pain, helping to speed recovery from injuries to soft tissues such as muscle,
tendon and ligaments.
What
will the procedure involve?
The skin over your
injury will be cleaned. Then local anaesthetic may be injected with a fine needle into the area of your injury, in order to
make the site numb.
Traumeel will be
injected into the site of the injury. Afterwards, a plaster will be placed on
the skin where the injection has been performed.
You will be given
advice about rest and appropriate exercise to perform after the injection.
What are the possible side effects?
As with any procedure
there can be side effects. There may be mild discomfort associated with having an injection.
Due to the injection
there may be a very small risk of infection, but this is minimal and no greater than for any injection. Sterile precautions
are taken throughout the procedure to prevent infection.
The injection may
also cause a temporary flare of pain.
Please be sure to ask the doctor beforehand if you have any questions about the injection, and also to inform
the doctor if any concerns arise after the procedure.
TRAUMEEL
(Information
sheet from Drugs.com)
TRAUMEEL® Injection Solution is an anti-inflammatory, anti-edematous, anti-exudative
combination formulation of 12 botanical substances and 1 mineral substance. TRAUMEEL® Injection Solution is officially classified
as a homeopathic combination remedy (1).
1. Botanical ingredients:
Arnica montana, radix (mountain arnica)
Calendula officinalis (marigold)
Hamamelis virginiana (witch hazel)
Millefolium (milfoil)
Belladonna (deadly nightshade)
Aconitum napellus (monkshood)
Chamomilla (chamomile)
Symphytum officinale (comfrey)
Bellis perennis (daisy)
Echinacea angustifolia (narrow-leafed cone flower)
Echinacea purpurea (purple cone flower)
Hypericum perforatum (St. John's
wort)
2. Mineral ingredients:
Hepar sulphuris calcareum (calcium sulfide)
Injection Solution: Each 2.0 ml ampule contains as active ingredients: Hepar sulphuris calcareum
8X 200.0 µl; Belladonna 3X 20.0 µl; Calendula officinalis 3X 20.0 µl; Chamomilla 4X 20.0 µl; Millefolium 4X 20.0 µl; Aconitum
napellus 3X 12.0 µl; Bellis perennis 3X 10.0 µl; Hypericum perforatum 3X 6.0 µl; Echinacea angustifolia 3X 5.0 µl; Echinacea
purpurea 3X 5.0 µl; Arnica montana, radix 2X 2.0 µl; Hamamelis virginiana 2X 2.0 µl; Symphytum officinale 6X 2.0 µl. Each
2.0 ml ampule contains as an inactive ingredient: Sterile isotonic sodium chloride solution.
CLINICAL PHARMACOLOGY
The exact mechanism of action of TRAUMEEL® Injection Solution is not fully understood.
Various cellular and biochemical pathways appear to be modulated by the product ingredients. The mechanism of action of TRAUMEEL®
Injection Solution does not appear to be the result of cyclooxygenase or lipoxygenase enzyme inhibition, as is the case with
nonsteroidal anti-inflammatory drugs (NSAIDs). TRAUMEEL® Injection Solution does not inhibit the arachidonic acid pathway
of prostaglandin synthesis. Instead, the mechanism of action of TRAUMEEL® Injection Solution appears to be the result of modulation
of the release of oxygen radicals from activated neutrophils, and inhibition of the release of inflammatory mediators (possibly
interleukin-1 from activated macrophages) and neuropeptides (2).
In vitro studies
show that the ingredients in TRAUMEEL® Injection Solution are noncytotoxic to granulocytes, lymphocytes, platelets, and endothelia,
which indicates that the defensive functions of these cells are preserved during treatment with TRAUMEEL® Injection Solution
(3).
The anti-inflammatory, anti-edematous, and anti-exudative effects of TRAUMEEL® Injection
Solution have been demonstrated in clinical trials as well as in in vivo experimental models including the carrageenin-induced edema test and the adjuvant arthritis test (3).
INDICATIONS AND USAGE
TRAUMEEL® Injection Solution is indicated for the treatment of symptoms associated
with inflammatory, exudative, and degenerative processes due to acute trauma (such as contusions, lacerations, fractures,
sprains, post-operative wounds, etc.), repetitive or overuse injuries (such as tendonitis, bursitis, epicondylitis, etc.),
and for minor aches and pains associated with such conditions. TRAUMEEL® Injection Solution is also indicated for the treatment
of minor aches and pains associated with backache, muscular aches, and the minor pain from rheumatoid arthritis, osteoarthritis, gouty arthritis, and ankylosing spondylitis.
CONTRAINDICATIONS
TRAUMEEL® Injection Solution is contraindicated in patients with a known hypersensitivity
to TRAUMEEL® Injection Solution or any of its ingredients (see ADVERSE REACTIONS ).
WARNINGS
If pain persists or worsens, if new symptoms occur, or if redness or swelling is present,
the patient should be carefully re-evaluated because these could be signs of a serious condition.
PRECAUTIONS
General:
Adverse effects with TRAUMEEL® Injection Solution are extremely rare. TRAUMEEL® Injection
Solution exhibits no known adverse renal, hepatic, cardiovascular, gastrointestinal or central nervous system effects.
Information for Patients:
No harmful or potentially hazardous side effects such as central nervous system depression
are known. TRAUMEEL® Injection Solution is generally well-tolerated. However, if symptoms persist or worsen, a physician should
be consulted (see WARNINGS ).
Drug Interactions:
TRAUMEEL® Injection Solution is not known to interact with other medications. Furthermore,
the administration of TRAUMEEL® Injection Solution can be safely augmented by the application of a topical dosage form of
TRAUMEEL®.
Drug/Laboratory Test Interactions:
TRAUMEEL® Injection Solution is not known to interact with any laboratory tests.
Carcinogenesis:
No studies have been performed to evaluate the carcinogenicity of TRAUMEEL® Injection
Solution. In world-wide post-marketing surveillance studies no evidence of carcinogenicity has been found (2).
Pregnancy:
Pregnancy Category C. In general, medications such as TRAUMEEL® Injection Solution that are classified as homeopathic are not known
to cause direct or indirect harm to the fetus. However, animal reproduction studies have not been performed and there are
no well-controlled studies in pregnant women. In cases of pregnancy or suspected pregnancy, TRAUMEEL® Injection Solution should be used only if potential benefits justify
potential risks to the fetus.
Nursing Mothers:
It is not known whether any of the ingredients in TRAUMEEL® Injection Solution are
excreted in human milk. However, because many drugs are excreted in human milk, TRAUMEEL® Injection Solution should be administered
with caution to nursing mothers.
Pediatric Use:
TRAUMEEL® Injection Solution can be safely administered to children as young as 2 years
(see DOSAGE AND ADMINISTRATION ).
ADVERSE REACTIONS
In rare cases, patients with hypersensitivity to botanicals of the Compositae family may experience an allergic reaction after the administration of TRAUMEEL® Injection Solution including anaphylactic reaction.
TRAUMEEL® Injection Solution ingredients of the Compositae family are:
Arnica montana, radix (mountain
arnica)
Calendula officinalis (marigold)
Millefolium (milfoil)
Chamomilla (chamomile)
Bellis perennis (daisy)
Echinacea angustifolia (narrow-leafed cone flower)
Echinacea purpurea (purple cone flower)
OVERDOSAGE
Due to the low concentration of active ingredients in homeopathic preparations such
as TRAUMEEL® Injection Solution, adverse reactions following overdosage are extremely unlikely. However, care must be taken
not to exceed the recommended dosage.
DOSAGE AND ADMINISTRATION
The dosage schedules listed below can be used as a general guide for the administration
of TRAUMEEL® Injection Solution. TRAUMEEL® Injection Solution shows individual differences in clinical response. Therefore,
the dosage for each patient should be individualized according to the patient's response to therapy. For best results, treatment
with TRAUMEEL® Injection Solution should be initiated immediately following injury or at the first sign of symptoms. TRAUMEEL®
Injection Solution may be administered until symptoms disappear.
TRAUMEEL® Injection Solution:
Adults and children above 6 years: 1 ampule daily for acute disorders, or 1 to 2 ampules 1 to 3 times weekly.
Children (2 to 6 years): Half the adult dosage. Discard unused solution.
TRAUMEEL® Injection Solution may be administered intravenously, intramuscularly, subcutaneously
or intradermally. TRAUMEEL® Injection Solution is indicated for peri-articular administration, and for intra-articular aseptic
conditions. If administration with a local anesthetic is desired, TRAUMEEL® Injection Solution may be mixed in a 1:1 ratio
with 1% or 2% lidocaine hydrochloride. Similar local anesthetics may also be used. The required dose of TRAUMEEL® Injection
Solution is first withdrawn from the ampule into the syringe. The local anesthetic is then withdrawn into the syringe, and
the syringe is then shaken briefly. Normally, about 0.5 to 1.0 milliliters of each drug is withdrawn into the syringe.
TRAUMEEL® Injection Solution should be administered using a narrow gauge needle (e.g.,
22 to 30 gauge). Note: Parenteral drug products like TRAUMEEL® Injection Solution should be inspected visually
for particulate matter and discoloration prior to administration whenever solution and container permit. TRAUMEEL® Injection
Solution is a clear, colorless solution. Discolored solutions should be discarded.
HOW SUPPLIED
TRAUMEEL® Injection Solution in 2.0 ml ampules:
Packs of 10: NDC 50114-7000-1.
Avoid freezing and excessive heat. Store at room temperature. Protect from light.
CAUTION: Rx only.
REFERENCES
1. The Homeopathic Pharmacopoeia of the United States (HPUS), 8 th
edition, Falls Church, Virginia, 1979; and the Homeopathic Pharmacopoeia of the United States Revision Service (HPRS),
1988.
2. Data on file, Heel GmbH, Baden-Baden, Germany.
3. Conforti A, et al . Experimental Studies on the Anti-inflammatory
Activity of a Homeopathic Preparation. Biomedical Therapy XV No.1:28-31, 1997.
This full prescribing information has been compiled in accordance with the Code of
Federal Regulations (CFR), 21 sections 201.56 and 201.57.
